Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) dropped 2% on Tuesday . The stock traded as low as $3.37 and last traded at $3.42. Approximately 3,259 shares traded hands during trading, a decline of 37% from the average daily volume of 5,184 shares. The stock had previously closed at $3.49.
Genenta Science Trading Down 2.0 %
The company has a fifty day simple moving average of $3.65 and a two-hundred day simple moving average of $4.33.
Genenta Science Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Featured Stories
- Five stocks we like better than Genenta Science
- Insider Trading – What You Need to Know
- Garmin Navigates to New Highs Driven By Wearables Trend
- Airline Stocks – Top Airline Stocks to Buy Now
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What is the NASDAQ Stock Exchange?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
